Guangzhou Bio-Gene Announces Oral Presentation at the 2021 ASCO Annual Meeting

June 3, 2021 12:08 UTC



GUANGZHOU, China--(BUSINESS WIRE)-- Guangzhou Bio-Gene, a clinical-stage biopharmaceutical company developing a pipeline of innovative oncology therapies, today announced the company will present at the 2021 American Society of Clinical Oncology ("ASCO") Annual Meeting taking place June 4-8th, 2021.

The presentation, entitled “The efficacy and safety of anti-CLL1 based CAR-T cells in children with relapsed or refractory acute myeloid leukemia: a multi-center interim analysis” will highlight Phase I clinical data demonstrating the safety and efficacy of BG1805, a potent anti-CLL1 CAR-T therapy, in R/R AML pediatric patients. An abstract of the presentation is currently available on ASCO website (

Presentation details are as follows:

Session Title:




Pediatric Oncology I

Session Date and Time:




June 5, 2021, 10:00 AM - 1:00 PM

About Guangzhou Bio-Gene

Guangzhou Bio-Gene is a clinical-stage biopharmaceutical company focused on innovative oncology therapeutics. Bio-Gene is developing a pipeline of autologous and allogeneic CAR-T therapies for the treatment of a broad range of cancers and other diseases. The company is headquartered in Guangzhou, China.


Guangzhou Bio-Gene
Guangchao Li, PhD
Senior Director, Business Development


Source: Guangzhou Bio-Gene

Back to news